China
Africa
Explore chapters and articles related to this topic
Plant-Based Production of Biosimilar Drug Products
Published in Laszlo Endrenyi, Paul Jules Declerck, Shein-Chung Chow, Biosimilar Drug Product Development, 2017
Kenny K. Y. So, Michael R. Marit, Michael D. McLean, J. Christopher Hall
The first demonstration of the successful expression of an IgG in plants was in 1989 (Hiatt et al., 1989); since then, improvements in the production of mAbs by plants have contributed to realistic proposals for the use of plant systems as an alternative platform for the production of therapeutic proteins. This is exemplified by research on plant-based biopharmaceuticals that has been conducted under sponsorship of the US Defense Advanced Research Projects Agency’s (DARPAs) “Blue Angel” project, with funding totaling more than $100 million as of 2013 (Bosch et al., 2013; Sheldon, 2012). Furthermore, although not an antibody, the FDA’s approval of Elelyso, which is a recombinant form of taliglucerase alpha produced by Protalix and Pfizer using carrot cell culture, in 2012 for the treatment of Gaucher’s disease substantiated the ability of a plant-based platform to produce clinically effective biopharmaceuticals (Maxmen, 2012; Sack et al., 2015a). In addition, the recent USFDA approval of ZMapp, an mAb cocktail produced in Nicotiana benthamiana for treatment of Ebola virus disease (Qiu et al., 2014), for use on a provisional emergency basis without clinical trials further confirms the viability of using plant-based systems for producing functional mAbs (McCarthy, 2014).
A systematic review of mathematical models of the Ebola virus disease
Published in International Journal of Modelling and Simulation, 2022
Suliman Jamiel M. Abdalla, Faraimunashe Chirove, Keshlan S. Govinder
Viral shedding data were used for different purposes. House et al [47]. employed viral shedding data to estimate model parameters, including the mean of the infectious period for high and low viraemia. Additionally, they aimed to explore the mechanism in which vaccines reduce infection. Nguyen et al [46]. employed the data to understand the impact of the within-host pathogen dynamics into the between-host dynamics and evaluate the impact of EVD vaccination. Martyushev et al [48]. explored how EVD therapies such as ZMapp, TKM-Ebola and Favipiravir mitigate Ebola virus spread. Further, they aimed to understand the relationship between EVD severity and Ebola virus replication.